Mixed Outlook for Select S&P 500 Stocks

March 27, 2026 at 15:17 UTC

4 min read
S&P 500 stocks performance chart highlighting TJX, Insulet, and Corpay trends

Key Points

  • Recent analysis highlights several S&P 500 (SPX) names with sharply different growth profiles
  • Off‑price retailer TJX shows steady sales gains and strong returns on capital
  • Lockheed Martin (LMT) and Henry Schein face slower growth and weakening profitability metrics
  • Insulet and Corpay are cited for rapid growth and improving capital efficiency

Diverging prospects across S&P 500 constituents

Recent commentary on a group of S&P 500 (SPX) companies underscores how varied fundamentals are within the index, with some businesses posting robust growth and rising returns on capital while others struggle with slower expansion and eroding profitability.

Across retailers, healthcare, payments, industrials, and financial services, the assessments focus on sales trends, returns on capital, and valuation multiples, highlighting where analysts see momentum or emerging pressure.

TJX: steady growth at an off‑price retail leader

TJX, an off‑price retailer with a market capitalization of about $175 billion, continues to lean on its model of buying excess inventory and selling brand‑name apparel and other goods at prices below department stores.

Same‑store sales growth averaged 3.9% over the past two years, indicating it is attracting both new and repeat shoppers. Revenue of $60.37 billion reflects its dominant market position, offsetting what is described as a subpar gross margin.

The company is also characterized by stellar and rising returns on capital, described as evidence that management is finding highly profitable ventures and capitalizing on attractive market opportunities. TJX shares recently traded at $158.46, or about 31.3 times forward earnings.

Insulet: rapid expansion in diabetes technology

Insulet, with a market capitalization of $15.35 billion, develops insulin delivery systems, notably its tubeless "Pod" technology sold through the Omnipod product line for people with diabetes.

The company recorded average constant‑currency revenue growth of 25.9% over the past two years, which is cited as evidence of its ability to expand internationally despite currency fluctuations.

Insulet’s free cash flow margin has increased by 30.1 percentage points over the last five years, giving it more capital to reinvest or return to shareholders. Rising returns on capital are also highlighted as a sign that management is finding more attractive investment opportunities. The stock is quoted at $218.55 per share, or 34.1 times forward earnings.

Corpay: business payments platform after rebrand

Corpay, which rebranded from FLEETCOR in 2024 and has a market capitalization of $19.95 billion, offers specialized payment solutions that help businesses manage vehicle expenses, corporate payments, and lodging costs with enhanced control and reporting.

The recent discussion presents Corpay as a notable S&P 500 (SPX) name within business payments, though detailed current‑period growth or profitability metrics are not provided in the available material.

Lockheed Martin: modest growth and narrowing profitability

Lockheed Martin (LMT), a defense and aerospace company headquartered in Maryland and known for the F‑35 aircraft, carries a market capitalization of $144.3 billion but faces slower growth relative to its industrial peers.

Its annual sales growth of 2.8% over the last five years lagged its sector peers, with its large revenue base cited as a factor making incremental demand harder to generate. Over the same period, earnings per share declined at a 2.6% annual rate, indicating that incremental sales were much less profitable.

Returns on capital are described as eroding, suggesting historical profit centers are aging. Lockheed Martin (LMT) shares recently changed hands at $629.25, implying a forward price‑to‑earnings ratio of 20.9.

Henry Schein: soft demand and pressures on core business

Henry Schein, a global distributor of healthcare products and services to dental practices, medical offices, and other healthcare facilities, has a market capitalization of $8.45 billion and manages a catalog of more than 300,000 products across over 5.3 million square feet of distribution space.

The company’s core business has underperformed, with organic revenue disappointing over the past two years, raising the possibility that acquisitions may be needed to reignite growth, according to the assessment.

Estimated sales growth of 4.1% over the next 12 months is described as soft and indicative of weaker demand, while returns on capital are said to be eroding. Henry Schein’s share price of $73.71 corresponds to a forward price‑to‑earnings ratio of 14.

S&P Global: long‑established data and ratings provider

S&P Global (SPGI), valued at $123.2 billion, provides credit ratings, market intelligence, commodity data, automotive analytics, and financial indices used by investors and businesses for decision‑making.

The company traces its roots to 1860, when it published a railroad industry manual, and is presented as an S&P 500 stock to watch, although the recent material does not specify current growth or profitability metrics.

Key Takeaways

  • Recent commentary draws a clear contrast between S&P 500 companies with rising returns on capital and those where profitability metrics are deteriorating.
  • Retail and medical technology names such as TJX and Insulet are highlighted for combining scale with sustained growth and improving cash generation.
  • Industrial and distribution businesses like Lockheed Martin and Henry Schein are characterized by slower sales trends and weakening return profiles.
  • Valuation multiples across the group range from Henry Schein’s lower forward P/E to higher multiples for faster‑growing firms such as Insulet and TJX, underscoring differing market expectations.